TP53 and neoplasm: However, the observed discrepancies in mutation frequencies with a decrease in the frequency of APC, TP53, and KRAS, in the PDX cohort compared to the clinical cohort, are indicative of the loss of the heterogeneity of a clinical tumor during modeling [16].